The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review
Open accessAbstract
Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy-induced peripheral neuropathy (CIPN). The health consequences of CIPN remain worrying as it is associated with several comorbidities and affects a specific population of patients already impacted by cancer, a strong driver for declines in older adults. The purpose of this review is to present a comprehensive overview of the long-term effects of CIPN in cancer patients and survivors. Pathophysiological mechanisms and risk factors are also presented. Neurotoxic mechanisms leading to CIPNs are not yet fully understood but involve neuronopathy and/or axonopathy, mainly associated with DNA damage, oxidative stress, mitochondria toxicity, and ion channel remodeling in the neurons of the peripheral nervous system. Classical symptoms of CIPNs are peripheral neuropathy with a "stocking and glove" distribution characterized by sensory loss, paresthesia, dysesthesia and numbness, sometimes associated with neuropathic pain in the most serious cases. Several risk factors can promote CIPN as a function of the anticancer drug considered, such as cumulative dose, treatment duration, history of neuropathy, combination of therapies and genetic polymorphisms. CIPNs are frequent in cancer patients with an overall incidence of approximately 38% (possibly up to 90% of patients treated with oxaliplatin). Finally, the long-term reversibility of these CIPNs remain questionable, notably in the case of platinum-based anticancer drugs and taxanes, for which CIPN may last several years after the end of anticancer chemotherapies. These long-term effects are associated with comorbidities such as depression, insomnia, falls and decreases of health-related quality of life in cancer patients and survivors. However, it is noteworthy that these long-term effects remain poorly studied, and only limited data are available such as in the case of bortezomib and thalidomide-induced peripheral neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microtubules as a target for anticancer drugs
Jordan, M. A., & Wilson, L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1317 · Cited by 4,000
Brenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T., Harousseau, J.-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,491
André, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., Chauhan, C., Gavin, P., Lavino, A., Lustberg, M. B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.0914 · Cited by 1,209
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4539 · Cited by 656
Platinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Argyriou, A. A., Bruna, J., Marmiroli, P., & Cavaletti, G. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.04.012 · Cited by 568
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Bad news from the brain: descending 5-HT pathways that control spinal pain processing
Suzuki, R., Rygh, L. J., & Dickenson, A. H. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.10.002 · Cited by 482
Arastu-Kapur, S., Anderl, J. L., Kraus, M., Parlati, F., Shenk, K. D., Lee, S. J., Muchamuel, T., Bennett, M. K., Driessen, C., Ball, A. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1950 · Cited by 408
Dougherty, P. M., Cata, J. P., Cordella, J. V., Burton, A., & Weng, H.-R. (2004) · Pain · doi:10.1016/j.pain.2004.01.021 · Cited by 369
Descoeur, J., Pereira, V., Pizzoccaro, A., Francois, A., Ling, B., Maffre, V., Couette, B., Busserolles, J., Courteix, C., Noel, J., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100134 · Cited by 368
Immune regulation of central nervous system functions: from sickness responses to pathological pain
WATKINS, L. R., & MAIER, S. F. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01443.x · Cited by 366
Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., & Cornblath, D. R. (1994) · Annals of Neurology · doi:10.1002/ana.410350310 · Cited by 363
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., & van de Poll-Franse, L. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1514 · Cited by 359
Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
Jaggi, A. S., & Singh, N. (2012) · Toxicology · doi:10.1016/j.tox.2011.10.019 · Cited by 358
Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., & Mao, J. J. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3939-0 · Cited by 337
Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons
Podratz, J. L., Knight, A. M., Ta, L. E., Staff, N. P., Gass, J. M., Genelin, K., Schlattau, A., Lathroum, L., & Windebank, A. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.017 · Cited by 320
Ledeboer, A., Jekich, B. M., Sloane, E. M., Mahoney, J. H., Langer, S. J., Milligan, E. D., Martin, D., Maier, S. F., Johnson, K. W., Leinwand, L. A., et al. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2006.10.012 · Cited by 308
Richardson, P. G., Sonneveld, P., Schuster, M. W., Stadtmauer, E. A., Facon, T., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07573.x · Cited by 305
Moreau, P., Avet-Loiseau, H., Facon, T., Attal, M., Tiab, M., Hulin, C., Doyen, C., Garderet, L., Randriamalala, E., Araujo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355081 · Cited by 303
Self-citationPeters, C. M., Jimenez-Andrade, J. M., Jonas, B. M., Sevcik, M. A., Koewler, N. J., Ghilardi, J. R., Wong, G. Y., & Mantyh, P. W. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.07.022 · Cited by 288
Diouf, B., Crews, K. R., Lew, G., Pei, D., Cheng, C., Bao, J., Zheng, J. J., Yang, W., Fan, Y., Wheeler, H. E., et al. (2015) · JAMA · doi:10.1001/jama.2015.0894 · Cited by 278
How Do Microtubule-Targeted Drugs Work? An Overview
Jordan, M., & Kamath, K. (2007) · Current Cancer Drug Targets · doi:10.2174/156800907783220417 · Cited by 270
Hershman, D. L., Weimer, L. H., Wang, A., Kranwinkel, G., Brafman, L., Fuentes, D., Awad, D., & Crew, K. D. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1278-0 · Cited by 264
The paradox of paclitaxel neurotoxicity: Mechanisms and unanswered questions
Gornstein, E., & Schwarz, T. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.016 · Cited by 252
How Taxol® stabilises microtubule structure
Amos, L. A., & Löwe, J. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)89002-4 · Cited by 248
Toll-Like Receptor 4 Signaling Contributes to Paclitaxel-Induced Peripheral Neuropathy
Li, Y., Zhang, H., Zhang, H., Kosturakis, A. K., Jawad, A. B., & Dougherty, P. M. (2014) · The Journal of Pain · doi:10.1016/j.jpain.2014.04.001 · Cited by 244
Ibáñez, C. F., & Simi, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2012.03.007 · Cited by 238
Glasmacher, A., Hahn, C., Hoffmann, F., Naumann, R., Goldschmidt, H., von Lilienfeld‐Toal, M., Orlopp, K., Schmidt‐Wolf, I., & Gorschlüter, M. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05914.x · Cited by 237
Li, Y., Adamek, P., Zhang, H., Tatsui, C. E., Rhines, L. D., Mrozkova, P., Li, Q., Kosturakis, A. K., Cassidy, R. M., Harrison, D. S., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1956-15.2015 · Cited by 235
Strumberg, D., Brügge, S., Korn, M. W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Möckel, C., Seeber, S., & Scheulen, M. E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf058 · Cited by 232
LaPointe, N. E., Morfini, G., Brady, S. T., Feinstein, S. C., Wilson, L., & Jordan, M. A. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.05.008 · Cited by 219
Broyl, A., Corthals, S. L., Jongen, J. L., van der Holt, B., Kuiper, R., de Knegt, Y., van Duin, M., el Jarari, L., Bertsch, U., Lokhorst, H. M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70206-0 · Cited by 219
Badros, A., Goloubeva, O., Dalal, J. S., Can, I., Thompson, J., Rapoport, A. P., Heyman, M., Akpek, G., & Fenton, R. G. (2007) · Cancer · doi:10.1002/cncr.22921 · Cited by 217
Presentation and management of docetaxel-related adverse effects in patients with breast cancer
Ho, M., & Mackey, J. (2014) · Cancer Management and Research · doi:10.2147/cmar.s40601 · Cited by 210
Rowinsky, E. K., Chaudhry, V., Cornblath, D. R., & Donehower, R. C. (1993) · PubMed · Cited by 208
Baldwin, R. M., Owzar, K., Zembutsu, H., Chhibber, A., Kubo, M., Jiang, C., Watson, D., Eclov, R. J., Mefford, J., McLeod, H. L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1590 · Cited by 204
Pike, C. T., Birnbaum, H. G., Muehlenbein, C. E., Pohl, G. M., & Natale, R. B. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/913848 · Cited by 202
Landowski, T. H., Megli, C. J., Nullmeyer, K. D., Lynch, R. M., & Dorr, R. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3684 · Cited by 202
Lavoie Smith, E. M., Li, L., Chiang, C., Thomas, K., Hutchinson, R. J., Wells, E. M., Ho, R. H., Skiles, J., Chakraborty, A., Bridges, C. M., et al. (2015) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12114 · Cited by 198
Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility
Park, S. B., Lin, C. S. Y., Krishnan, A. V., Goldstein, D., Friedlander, M. L., & Kiernan, M. C. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0248 · Cited by 198
Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening
Verstappen, C. C. P., Koeppen, S., Heimans, J. J., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000154642.45474.28 · Cited by 196
Attal, N., Bouhassira, D., Gautron, M., Vaillant, J. N., Mitry, E., Lepère, C., Rougier, P., & Guirimand, F. (2009) · Pain · doi:10.1016/j.pain.2009.03.024 · Cited by 195
Mannelli, L. D. C., Zanardelli, M., Failli, P., & Ghelardini, C. (2012) · Journal of Pain · doi:10.1016/j.jpain.2011.11.009 · Cited by 194
Egbelakin, A., Ferguson, M. J., MacGill, E. A., Lehmann, A. S., Topletz, A. R., Quinney, S. K., Li, L., McCammack, K. C., Hall, S. D., & Renbarger, J. L. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.22845 · Cited by 192
Xiao, W. H., & Bennett, G. J. (2012) · Pain · doi:10.1016/j.pain.2011.12.011 · Cited by 191
Khrunin, A. V., Moisseev, A., Gorbunova, V, & Limborska, S. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.45 · Cited by 190
Tofthagen, C., Donovan, K. A., Morgan, M. A., Shibata, D., & Yeh, Y. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-1905-5 · Cited by 190
Beijers, A. J. M., Mols, F., & Vreugdenhil, G. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2242-z · Cited by 189
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy
Zheng, H., Xiao, W. H., & Bennett, G. J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.023 · Cited by 184
Dysregulation of Cellular Calcium Homeostasis in Chemotherapy-Evoked Painful Peripheral Neuropathy
Siau, C., & Bennett, G. J. (2006) · Anesthesia & Analgesia · doi:10.1213/01.ane.0000204318.35194.ed · Cited by 183
Toxic neuropathy in patients with pre-existing neuropathy
Chaudhry, V., Chaudhry, M., Crawford, T. O., Simmons-O’Brien, E., & Griffin, J. W. (2003) · Neurology · doi:10.1212/01.wnl.0000043691.53710.53 · Cited by 173
Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy
Chaudhry, V., Cornblath, D. R., Polydefkis, M., Ferguson, A., & Borrello, I. (2008) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2008.00193.x · Cited by 172
Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia
Sissung, T. M., Mross, K., Steinberg, S. M., Behringer, D., Figg, W. D., Sparreboom, A., & Mielke, S. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.06.017 · Cited by 170
Nature as a remarkable chemist: a personal story of the discovery and development of Taxol
Wani, M. C., & Horwitz, S. B. (2014) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000063 · Cited by 169
Doyle, T., Chen, Z., Muscoli, C., Bryant, L., Esposito, E., Cuzzocrea, S., Dagostino, C., Ryerse, J., Rausaria, S., Kamadulski, A., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6343-11.2012 · Cited by 168
Mohty, B., El-Cheikh, J., Yakoub-Agha, I., Moreau, P., Harousseau, J.-L., & Mohty, M. (2010) · Haematologica · doi:10.3324/haematol.2009.012674 · Cited by 167
Adverse interactions between antifungal azoles and vincristine: review and analysis of cases
Moriyama, B., Henning, S. A., Leung, J., Falade‐Nwulia, O., Jarosinski, P., Penzak, S. R., & Walsh, T. J. (2012) · Mycoses · doi:10.1111/j.1439-0507.2011.02158.x · Cited by 164
Eckhoff, L., Knoop, A., Jensen, M., & Ewertz, M. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.024 · Cited by 163
Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia
Ramchandren, S., Leonard, M., Mody, R. J., Donohue, J. E., Moyer, J., Hutchinson, R., & Gurney, J. G. (2009) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2009.00230.x · Cited by 163
Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., Hauge, E. R., Dahl, O., & Fossa, S. D. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp413 · Cited by 162
Quantitative Sensory Findings in Patients With Bortezomib-Induced Pain
Cata, J. P., Weng, H.-R., Burton, A. W., Villareal, H., Giralt, S., & Dougherty, P. M. (2007) · The Journal of Pain · doi:10.1016/j.jpain.2006.09.014 · Cited by 160
Tanabe, Y., Hashimoto, K., Shimizu, C., Hirakawa, A., Harano, K., Yunokawa, M., Yonemori, K., Katsumata, N., Tamura, K., Ando, M., et al. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0352-x · Cited by 160
Gauchan, P., Andoh, T., Kato, A., & Kuraishi, Y. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.04.029 · Cited by 160
Long term effects of vincristine on the peripheral nervous system
Postma, T. J., Benard, B. A., Huijgens, P. C., Ossenkoppele, G. J., & Heimans, J. J. (1993) · Journal of Neuro-Oncology · doi:10.1007/bf01050259 · Cited by 154
Glendenning, J., Barbáchano, Y., Norman, A. R., Dearnaley, D. P., Horwich, A., & Huddart, R. A. (2010) · Cancer · doi:10.1002/cncr.24981 · Cited by 153
Dzagnidze, A., Katsarava, Z., Makhalova, J., Liedert, B., Yoon, M., Kaube, H., Limmroth, V., & Thomale, J. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0523-07.2007 · Cited by 152
Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies
Cavaletti, G., & Jakubowiak, A. J. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.483303 · Cited by 149
Paclitaxel: new uses for an old drug
Dong, Z., Zhang, D., Yang, R., & Wang, S. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s56801 · Cited by 149
Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine
Boyette-Davis, J. A., Cata, J. P., Driver, L. C., Novy, D. M., Bruel, B. M., Mooring, D. L., Wendelschafer-Crabb, G., Kennedy, W. R., & Dougherty, P. M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2047-z · Cited by 148
Dimopoulos, M. A., Mateos, M., Richardson, P. G. G., Schlag, R., Khuageva, N. K., Shpilberg, O., Kropff, M. H., Špıčka, I., Palumbo, A. P., Wu, K. L., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01533.x · Cited by 147
Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199
Schneider, B. P., Li, L., Radovich, M., Shen, F., Miller, K. D., Flockhart, D. A., Jiang, G., Vance, G. H., Gardner, L., Vatta, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0586 · Cited by 144
Effect of paclitaxel on transient receptor potential vanilloid 1 in rat dorsal root ganglion
Hara, T., Chiba, T., Abe, K., Makabe, A., Ikeno, S., Kawakami, K., Utsunomiya, I., Hama, T., & Taguchi, K. (2013) · Pain · doi:10.1016/j.pain.2013.02.023 · Cited by 142
Sissung, T. M., Baum, C. E., Deeken, J. F., Price, D. K., Aragon‐Ching, J. B., Steinberg, S. M., Dahut, W. L., Sparreboom, A., & Figg, W. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4230 · Cited by 140
Pharmacokinetics and toxicity of docetaxel: Role of CYP3A, MDR1, and GST polymorphisms
Tran, A., Jullien, V., Alexandre, J., Rey, E., Rabillon, F., Girre, V., Dieras, V. C., Pons, G., Goldwasser, F., & Tréluyer, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.02.003 · Cited by 139
Thalidomide sensory neurotoxicity
Cavaletti, G., Beronio, A., Reni, L., Ghiglione, E., Schenone, A. E., Briani, C., Zara, G., Cocito, D., Isoardo, G., Ciaramitaro, P., et al. (2004) · Neurology · doi:10.1212/wnl.62.12.2291 · Cited by 135
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
Leskelä, S., Jara, C., Leandro-Garcia, L. J., Martínez, A., García-Donás, J., Hernando, S., Hurtado, A., Vicario, J. C. C., Montero‐Conde, C., Landa, I., et al. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.13 · Cited by 132
Ventzel, L., Jensen, A. B., Jensen, A. R., Jensen, T. S., & Finnerup, N. B. (2015) · Pain · doi:10.1097/j.pain.0000000000000404 · Cited by 131
Paclitaxel and docetaxel in the treatment of breast cancer
Saloustros, E. S., Mavroudis, D., & Georgoulias, V. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2603 · Cited by 129
Neuropathy in multiple myeloma treated with thalidomide
Plasmati, R., Pastorelli, F., Cavo, M., Petracci, E., Zamagni, E., Tosi, P., Cangini, D., Tacchetti, P., Salvi, F., Bartolomei, I., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267271.18475.fe · Cited by 126
Carozzi, V., Renn, C. L., Bardini, M., Fazio, G., Chiorazzi, A., Meregalli, C., Oggioni, N., Shanks, K., Quartu, M., Serra, M. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072995 · Cited by 123
Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence
Balayssac, D., Ferrier, J., Descoeur, J., Ling, B., Pezet, D., Eschalier, A., & Authier, N. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.543417 · Cited by 119
Self-citationReyes‐Gibby, C. C., Morrow, P. K. H., Buzdar, A. U., & Shete, S. S. (2009) · Journal of Pain · doi:10.1016/j.jpain.2009.04.006 · Cited by 118
Pignata, S., Placido, S. D., Biamonte, R., et al. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-5 · Cited by 116
CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxel
Hertz, D. L., Roy, S., Motsinger‐Reif, A. A., Drobish, A. A., Clark, L. S., McLeod, H. L., Carey, L., & Dees, E. C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt018 · Cited by 116
Argyriou, A. A., Cavaletti, G., Antonacopoulou, A. G., Genazzani, A. A., Briani, C., Bruna, J., Terrazzino, S., Velasco, R., Alberti, P., Campagnolo, M., et al. (2013) · Cancer · doi:10.1002/cncr.28234 · Cited by 115
Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas
Haim, N., Epelbaum, R., Ben-Shahar, M., Yarnitsky, D., Simri, W., & Robinson, E. (1994) · Cancer · Cited by 115
Hong, J., Tian, J., & Wu, L. (2014) · Current Oncology · doi:10.3747/co.21.1984 · Cited by 113
Poruchynsky, M. S., Sackett, D. L., Robey, R. W., Ward, Y., Annunziata, C. M., & Fojo, T. (2008) · Cell Cycle · doi:10.4161/cc.7.7.5625 · Cited by 110
Ji, X., Qian, N., Zhang, T., Li, J., Li, X., Wang, P., Zhao, D., Huang, G., Zhang, L., Zhou, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060733 · Cited by 109
Barrière, D. A., Rieusset, J., Chanteranne, D., Busserolles, J., Chauvin, M., Chapuis, L., Salles, J., Dubray, C., & Morio, B. (2011) · Pain · doi:10.1016/j.pain.2011.11.019 · Cited by 108
Staff, N. P., Podratz, J. L., Grassner, L., Lange, M. L. B., Paz, J., Knight, A. M., Loprinzi, C. L., Trushina, E. V., & Windebank, A. J. (2013) · NeuroToxicology · doi:10.1016/j.neuro.2013.09.001 · Cited by 108
Jain, P., Gulati, S., Seth, R. K., Bakhshi, S., Toteja, G. S., & Pandey, R. M. (2013) · Journal of Child Neurology · doi:10.1177/0883073813491829 · Cited by 103
Shimozuma, K., Ohashi, Y., Takeuchi, A., Aranishi, T., Morita, S., Kuroi, K., Ohsumi, S., Makino, H., Katsumata, N., Kuranami, M., et al. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1492-x · Cited by 101
Carozzi, V., Canta, A., Oggioni, N., Sala, B., Chiorazzi, A., Meregalli, C., Bossi, M., Marmiroli, P., & Cavaletti, G. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.09.004 · Cited by 101
Rodent Models of Chemotherapy-Induced Peripheral Neuropathy
Höke, A., & Ray, M. (2014) · ILAR Journal · doi:10.1093/ilar/ilt053 · Cited by 101
CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity
de Graan, A. M., Elens, L., Sprowl, J. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3786 · Cited by 101
Schneider, B. P., Zhao, F., Wang, M., Stearns, V., Martino, S., Jones, V. E., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8446 · Cited by 100
The Nav1.9 Channel Is a Key Determinant of Cold Pain Sensation and Cold Allodynia
Lolignier, S., Bonnet, C., Gaudioso, C., Noël, J., Ruel, J., Amsalem, M., Ferrier, J., Rodat‐Despoix, L., Bouvier, V., Aissouni, Y., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.027 · Cited by 97
Beijers, A. J. M., Mols, F., Dercksen, W., Driessen, C. M. L., & Vreugdenhil, G. (2014) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0086 · Cited by 95
Taxane induced neuropathy in patients affected by breast cancer: Literature review
Iuliis, F. D., Taglieri, L., Salerno, G., Lanza, R., & Scarpa, S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.04.011 · Cited by 93
Fernyhough, P., Smith, D. R., Schapansky, J., der Ploeg, R. V., Gardiner, N. J., Tweed, C. W., Kontos, A., Freeman, L. J., Purves-Tyson, T. D., & Glazner, G. W. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3127-04.2005 · Cited by 91
Tubulin inhibitors: a patent review
Liu, Y.-M., Chen, H.-L., Lee, H.-Y., & Liou, J. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.859247 · Cited by 89
Leach, C. R., Bellizzi, K. M., Hurria, A., & Reeve, B. B. (2016) · Cancer · doi:10.1002/cncr.29914 · Cited by 81
Jiménez‐Andrade, J. M., Peters, C. M., Mejia, N. A., Ghilardi, J. R., Kuskowski, M. A., & Mantyh, P. W. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.06.043 · Cited by 78
Paclitaxel (Taxol) induces cumulative mild neurotoxicity
van Gerven, J., Moll, J. W. B., van den Bent, M. J., Bontenbal, M., van der Burg, M. E. L., Verweij, J., & Vecht, C. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90459-6 · Cited by 77
Therapy‐related peripheral neuropathy in multiple myeloma patients
Morawska, M., Grząśko, N., Kostyra, M., Wojciechowicz, J., & Hus, M. (2014) · Hematological Oncology · doi:10.1002/hon.2149 · Cited by 75
Bortezomib-induced peripheral neurotoxicity: an update
Argyriou, A. A., Cavaletti, G., Bruna, J., Kyritsis, A. P., & Kalofonos, H. P. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1316-5 · Cited by 75
Vincenzi, B., Frezza, A. M., Schiavon, G., Spoto, C., Addeo, R., Catalano, V., Graziano, F., Santini, D., & Tonini, G. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1667-5 · Cited by 75
Why and how to study the fate of cancer survivors
Ganz, P. A. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00489-1 · Cited by 74
Live‐cell analysis of mitotic spindle formation in taxol‐treated cells
Hornick, J. E., Bader, J. R., Tribble, E. K., Trimble, K., Breunig, J. S., Halpin, E. S., Vaughan, K. T., & Hinchcliffe, E. H. (2008) · Cell Motility and the Cytoskeleton · doi:10.1002/cm.20283 · Cited by 70
Beijers, A. J. M., Vreugdenhil, G., Oerlemans, S., Eurelings, M., Minnema, M. C., Eeltink, C., van de Poll-Franse, L. V., & Mols, F. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-3032-y · Cited by 68
Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial
Shinde, S. S., Seisler, D. K., Soori, G. S., Atherton, P. J., Pachman, D. R., Lafky, J. M., Ruddy, K. J., & Loprinzi, C. L. (2015) · Supportive Care in Cancer · doi:10.1007/s00520-015-2807-5 · Cited by 67
Velasco, R., Petit, J., Clapés, V., Verdú, E., Navarro, X., & Bruna, J. (2010) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2010.00248.x · Cited by 66
Custodio, A., Moreno‐Rubio, J., Aparicio, J., Gallego-Plazas, J., Yayá, R., Maurel, J., Higuera, O., Burgos, E., Ramos, D., Calatrava, A. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt546 · Cited by 64
Oxaliplatin-Induced Neuropathy in Colorectal Cancer: Many Questions With Few Answers
Zedan, A. H., Hansen, T. F., Svenningsen, Å. F., & Vilholm, O. J. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.11.004 · Cited by 62
Abd-Elsayed, A. A., Ikeda, R., Jia, Z., Ling, J., Zuo, X., Li, M., & Gu, J. G. (2015) · Molecular Pain · doi:10.1186/s12990-015-0048-8 · Cited by 62
Chemotherapy-induced peripheral neuropathies in hematological malignancies
Jongen, J. L. M., Broijl, A., & Sonneveld, P. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1632-x · Cited by 59
Tacchetti, P., Terragna, C., Galli, M., Zamagni, E., Petrucci, M. T., Pezzi, A., Montefusco, V., Martello, M., Tosi, P., Baldini, L., et al. (2014) · American Journal of Hematology · doi:10.1002/ajh.23835 · Cited by 57
Delayed emotional recovery after taxane‐based chemotherapy
Thornton, L. M., Carson, W. E., Shapiro, C. L., Farrar, W. B., & Andersen, B. L. (2008) · Cancer · doi:10.1002/cncr.23589 · Cited by 57
Gilchrist, L. S., Tanner, L. R., & Ness, K. K. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26204 · Cited by 57
Moser, E. C., Noordijk, E. M., Carde, P. P., Tirelli, U., Baars, J. W., Thomas, J., Bron, D., Meerwaldt, J. H., Glabbeke, M. M. V., Raemaekers, J. M. M., et al. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.038 · Cited by 56
Naumann, R., Mohm, J., Reuner, U., Kroschinsky, F., Rautenstrauss, B. W., & Ehninger, G. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03126.x · Cited by 55
Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats
Tomaszewski, A., & Büsselberg, D. (2006) · NeuroToxicology · doi:10.1016/j.neuro.2006.07.005 · Cited by 55
Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma
Kim, B., Park, H.-R., Roh, H., Jeong, D., Kim, B. S., Park, K. W., Cho, S. C., So, Y. T., Oh, S. Y., & Kim, S. J. (2010) · Quality of Life Research · doi:10.1007/s11136-010-9670-0 · Cited by 52
Li, S., Xue, F., Cheng, Z., Yang, X., Wang, S., Geng, F., & Pan, L. (2009) · International Journal of Hematology · doi:10.1007/s12185-009-0409-z · Cited by 52
Tariman, J. D., Love, G., McCullagh, E. J., & Sandifer, S. (2008) · Clinical journal of oncology nursing · doi:10.1188/08.cjon.s1.29-35 · Cited by 52
Kumamoto, K., Ishibashi, K., Okada, N., Tajima, Y., Kuwabara, K., KUMAGAI, Y., Baba, H., Haga, N., & Ishida, H. (2013) · Oncology Letters · doi:10.3892/ol.2013.1467 · Cited by 48
Hall, E., Cameron, D., Waters, R., Barrett-Lee, P. J., Ellis, P., Russell, S., Bliss, J. M., & Hopwood, P. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.06.007 · Cited by 47
Richardson, P. G. G., Laubach, J. P., Schlossman, R. L., Mitsiades, C. S., & Anderson, K. C. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0115 · Cited by 47
Stefansson, M., & Nygren, P. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1197420 · Cited by 45
Terrazzino, S., Argyriou, A. A., Cargnin, S., Antonacopoulou, A. G., Briani, C., Bruna, J., Velasco, R., Alberti, P., Campagnolo, M., Lonardi, S., et al. (2015) · Journal of the Peripheral Nervous System · doi:10.1111/jns.12110 · Cited by 43
Sharawy, N., Rashed, L. A., & Youakim, M. F. (2015) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2015.02.003 · Cited by 42
Thalidomide in multiple myeloma
Richardson, P. G. G., Hideshima, T., & Anderson, K. C. (2002) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(02)00168-3 · Cited by 41
Mannelli, L. D. C., Zanardelli, M., Landini, I., Pacini, A., Ghelardini, C., Mini, E., Bencini, A., Valtancoli, B., & Failli, P. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.01.023 · Cited by 40
Wang, C., Cherng, W., Yang, N., Hsu, C.-M., Yeh, C., Lan, Y.-J., Wang, J., & Verma, S. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00543.2007 · Cited by 39
Minařík, J., Pavlíček, P., Pour, L., Pika, T., Maisnar, V., Špıčka, I., Jarkovský, J., Krejčí, M., Bačovský, J., Radocha, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123866 · Cited by 39
Peng, Z., Wang, Q., Gao, J., Ji, Z., Yuan, J., Tian, Y., & Shen, L. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2194-x · Cited by 38
Javle, M. M., & Hsueh, C.-T. (2010) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-3-11 · Cited by 38
Myelin structure is unaltered in chemotherapy-induced peripheral neuropathy
Gilardini, A., Avila, R. L., Oggioni, N., Rodriguez‐Menendez, V., Bossi, M., Canta, A., Cavaletti, G., & Kirschner, D. A. (2011) · NeuroToxicology · doi:10.1016/j.neuro.2011.10.010 · Cited by 37
Vatandoust, S., Joshi, R., Pittman, K. B., Esterman, A., Broadbridge, V. T., Adams, J., Singhal, N., Yeend, S., & Price, T. J. (2013) · Supportive Care in Cancer · doi:10.1007/s00520-013-2004-3 · Cited by 34
Ibi, D., Nitta, A., Ishige, K., Cen, X., Ohtakara, T., Nabeshima, T., & Ito, Y. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2009.09.004 · Cited by 32
García‐Sánz, R., Corchete, L. A., Alcoceba, M., Chillón, C., Jiménez, C., Prieto, I., García‐Álvarez, M., Puig, N., Rapado, I., Barrio, S., et al. (2016) · Hematological Oncology · doi:10.1002/hon.2337 · Cited by 29
Jamieson, S. M. F., Liu, J., Hsu, T., Baguley, B. C., & McKeage, M. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601012 · Cited by 26
Thibault, K., Rivals, I., M’Dahoma, S., Dubacq, S., Pezet, S., & Calvino, B. (2013) · Journal of Molecular Neuroscience · doi:10.1007/s12031-013-0095-4 · Cited by 25
Earl, H. M., Connolly, S., Latoufis, C., Eagle, K., Ash, C. M., Fowler, C. J., & Souhami, R. L. (1998) · Sarcoma · doi:10.1080/13577149878055 · Cited by 24
Gracias, N. G., Cummins, T., Kelley, M. R., Basile, D. P., Iqbal, T. R., & Vasko, M. R. (2010) · NeuroToxicology · doi:10.1016/j.neuro.2010.09.006 · Cited by 24
Yang, Y., Zhang, Y., Lin, G.-A., Xie, H.-Q., Pan, H., Huang, B.-Q., Liu, J., Liu, H., Zhang, N., Li, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089583 · Cited by 23
Mateos, M. (2012) · Leukemia Research · doi:10.1016/s0145-2126(12)70007-3 · Cited by 20
Engelen, M. J. A., Snel, B. J., Schaapveld, M., Pras, E., de Vries, E. G. E., Gietema, J. A., van der Zee, A. G. J., & Willemse, P. H. B. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.006 · Cited by 16
Liew, E., Thyagu, S., Atenafu, E. G., Alibhai, S. M. H., & Brandwein, J. M. (2013) · Leukemia Research · doi:10.1016/j.leukres.2013.09.018 · Cited by 12
Cited by
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Mechanisms of Chemotherapy-Induced Peripheral Neuropathy
Zajączkowska, R., Kocot-Kępska, M., Leppert, W., Wrzosek, A., Mika, J., & Wordliczek, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061451 · Cited by 829
A Practical Review of Proteasome Pharmacology
Thibaudeau, T. A., & Smith, D. M. (2019) · Pharmacological Reviews · doi:10.1124/pr.117.015370 · Cited by 344
A systematic review of rehabilitation and exercise recommendations in oncology guidelines
Stout, N. L., Santa Mina, D., Lyons, K. D., Robb, K., & Silver, J. K. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21639 · Cited by 286
Duregon, F., Vendramin, B., Bullo, V., Gobbo, S., Cugusi, L., Di Blasio, A., Neunhaeuserer, D., Zaccaria, M., Bergamin, M., & Ermolao, A. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.002 · Cited by 196
Metadata
- Authors
- Kerckhove, N., Collin, A., Condé, S., Chaleteix, C., Pezet, D., & Balayssac, D.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2017-02-24
- Volume
- 8
- Pages
- 86-86
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2591526702
- Cited by
- 350
- References
- 157
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.